Journal News

New drug shows promise against Toxoplasmosis

Elizabeth Chapin
By Elizabeth Chapin
July 15, 2022

Findings from a new University of Kentucky College of Medicine study published in the Journal of Biological Chemistry May 28 may lead to a new treatment against Toxoplasma gondii, the parasite that causes toxoplasmosis.

The Centers for Disease Control and Prevention reports that an estimated 40 million people in the U.S. carry the parasite T. gondii, but very few have symptoms because the immune system usually keeps the parasite from causing illness. However, toxoplasmosis can have severe consequences for women newly infected during pregnancy and anyone with a compromised immune system.

Those who have severe toxoplasmosis can harbor a cyst version of the parasite within brain and muscle tissue. These cysts are responsible for causing serious disease, especially in people who are immunocompromised. 

The labs of Matthew Gentry, Ph.D., and Craig Vander Kooi, Ph.D., in the Department of Molecular and Cellular Biochemistry, Anthony Sinai, Ph.D., in the Department of Microbiology, Immunology and Molecular Genetics, and Zhong-Yin Zhang, Ph.D., at the Purdue Institute for Drug Discovery, collaborated to develop a drug that targets the cyst form of the parasite.

In previous research, Gentry identified an enzyme in T. gondii called TgLaforin, which he hypothesized was critical in allowing the parasite to access energy from a carbohydrate storage molecule. The team developed a new drug that inhibits TgLaforin with the goal of preventing enzymes from accessing and providing energy to the parasite.

While there are FDA-approved drugs to treat the symptoms of toxoplasmosis, no current therapeutics target the cyst form of the parasite.

The new discovery was made possible thanks to the multidisciplinary collaboration of experts from the four labs, says Gentry.

Courtesy of Kit Donohue in the Gentry lab at the University of Kentucky
 
University of Kentucky College of Medicine researchers (left to right) Tiantian Chen, Robert Murphy, Matthew Gentry and Craig Vander Kooi.

Robert Murphy, Ph.D., a member of the Gentry and Sinai labs, conducted initial experiments that characterized TgLaforin and provided a baseline for understanding the enzyme’s function.

Tiantian Chen, a graduate student in Vander Kooi’s lab, generated models of TgLaforin using a new program called AlphaFold2, which is an artificial intelligence algorithm that provides valuable insights into research. Chen generated models that provided a picture of the enzyme that demonstrated TgLaforin was a unique and possible drug target.

Jianping Lin, Ph.D., a postdoc in Zhang’s lab, then used information generated by Murphy and Chen in combination with novel techniques in chemistry to generate the first version of a future anti-Toxoplasma drug.

“I was excited to find that the drug was effective against TgLaforin in test tubes and that it prevented TgLaforin from performing its normal activity against a variety of substrates, including carbohydrates,” said Murphy.

Future work from these labs will test the drug on parasites. The team will then seek to increase its potency and selectivity and adapt its chemical properties to allow for animal studies.

“This study is a great example of what Provost DiPaola consistently promotes regarding transdisciplinary research,” Gentry said. “This work was a true team effort and it is very exciting to see where we take it next.”

This article originally appeared on the University of Kentucky website. It was republished with permission. Robert Murphy contributed to the report.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Elizabeth Chapin
Elizabeth Chapin


Elizabeth Chapin is a senior research information specialist at the University of Kentucky.

Related articles

JBC: Snug as a bug in the mud
Martin J. Spiering
From the journals: September 2018
Courtney Chandler, Isha Dey & Sasha Mushegian
From the journals: May 2018
Sasha Mushegian & Laurel Oldach
From the journals: JBC
Isabel Casas
From the journals: JBC
Isabel Casas

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

From the journals: MCP
Journal News

From the journals: MCP

Aug. 12, 2022

Analysis of large samples of proteins just got an upgrade. Read about the latest breakthroughs in proteomics in these papers from the journal Molecular & Cellular Proteomics.

Is location everything?
Journal News

Is location everything?

Aug. 9, 2022

A lab at the University of Illinois Chicago develops site-specific tools to probe the cellular function of cholesterol.

Did gonorrhea give us grandparents?
News

Did gonorrhea give us grandparents?

Aug. 9, 2022

UC San Diego researchers track evolution of gene variant that supports cognitive health in older humans but may have first emerged to protect against bacteria.

Why researchers are studying menstrual blood
News

Why researchers are studying menstrual blood

Aug. 7, 2022

Some scientists are challenging the conventional view that menstrual effluent is merely a waste product.

From the journals: JBC
Journal News

From the journals: JBC

Aug. 5, 2022

Defining functional redundancy in mycobacteria. Finding aqueous pores in sodium channels. Identifying new substrates for a ubiquitin ligase. Read about papers on these topics.

Cannabis hyperemesis and the cure that burns
Feature

Cannabis hyperemesis and the cure that burns

Aug. 3, 2022

When chronic users of marijuana show up in the ER with uncontrollable vomiting, physicians have a salve that can relieve their pain. Scientists aren’t sure why it works.